Trial · NCT05527340
Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.
NCT05527340, Phase 2, Active not recruiting, PETHEMA Foundation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. Trials, record NCT05527340. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05527340
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.
- NCT number
- NCT05527340
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 140 participants, estimated
- Lead sponsor
- PETHEMA Foundation
- Conditions
- Multiple Myeloma
- Interventions
- Iberdomide, Dexamethasone, Daratumumab
- First posted
- 2022-09-02
- Last updated
- 2026-05-08
- Other registries' IDs
- eudract:2021-002190-25
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate (ORR) | Throught the study period. Approximately 6 years. | The percentage of participants with a confirmed partial response (PR) or better (PR, Very good partial response (VGPR), Complete response (CR), stringent complete response (sCR)).Response rates will be monitored monthly, but the study will report the % of patients achieving CR rate at month 12, 18, 24 and yearly thereafter. |
| Primary | Complete Response Rate (CRR) | Throught the study period. Approximately 6 years. | The percentage of participants with a confirmed complete response (CR) or better (stringent complete response (CR, sCR). |
| Secondary | Minimal Residual Disease (MRD) negativity rate | Throught the study period. Approximately 6 years. | The percentage of participants who are MRD negative by next-generation flow cytometry (NGF), PET/CT, and mass spectrometry. |
| Secondary | Progression-Free Survival (PFS) | Throught the study period. Approximately 6 years. | Time from the date of randomization until the earliest date of documented disease progression or death due to any cause. |
| Secondary | Overall Survival (OS) | Throught the study period. Approximately 6 years. | Time from the date of randomization until the date of death due to any cause |
| Secondary | Changes in the immune profiling. | Throught the study period. Approximately 6 years. | Relative distribution and immunophenotype of inmune profiling from baseline onto treatment, remission and disease progression. |
| Secondary | Health status/quality of life | Baseline and throught the first 24 months. | Global health status/quality of life based on patient reported outcome: EQ-5D/5L questionnaire. |
| Secondary | Health status/quality of life | Baseline and throught the first 24 months. | Global health status/quality of life based on patient reported outcome: QLQ-C30 questionnaire. |
| Secondary | Health status/quality of life | Baseline and throught the first 24 months. | Global health status/quality of life based on patient reported outcome: MY20 questionnaire. |
| Secondary | Frequency and percentage of deaths and primary cause of death. | Throught the study period. Approximately 6 years. | Incidence of deaths and primary cause of death for safety analysis. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers13
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05527340
GET https://conductscience.org/api/trials/v1/NCT05527340/registered